Tiziana's Foralumab Hits Goals in MS Phase 2 Trial
Tiziana Life Sciences announced positive results from a phase 2 trial of Foralumab in secondary progressive multiple sclerosis. The trial met primary endpoints, showing reduced neuroinflammation and safety. Secondary endpoints, including fatigue and EDSS scores, also showed statistical significance. The company plans to advance the 50 microgram dose in future studies.
How this was made

The 30-second read
Why it matters
The article claims the trial met the primary endpoint of reduced neuroinflammation on PET and also reports statistical significance in secondary endpoints (EDSS and fatigue), which would be a meaningful clinical development signal if confirmed in a full dataset and filing.
Market read
If validated, the Phase 2 readout is a development catalyst for the company’s MS pipeline and could shift expectations for subsequent trials and partnering discussions.
What to watch
The transcript excerpt omits key trial specifics (n per arm, adverse events, imaging quantification method, and whether results are clinically meaningful beyond PET and fatigue scores).
Background
Tiziana Life Sciences CEO describes a Phase 2 placebo-controlled, double-blind trial of furalumab (intranasal, CD3-binding fully human monoclonal antibody) in secondary progressive multiple sclerosis, with PET imaging of activated microglia and fatigue/EDSS as secondary endpoints.
Market effects
Positive Phase 2 readout in SPMS could modestly improve sentiment toward neuroinflammation and intranasal biologic approaches in MS R&D.
No clear regional market catalyst beyond biotech sentiment.
MS trial outcomes can influence global biotech risk appetite for CNS immunology programs.
Counterpoint
Statistical significance is described as borderline (p=0.168 reported), and the article excerpt does not provide effect size, durability, or full safety details.
Key entities
- companyTiziana Life Sciences
Subject of the presentation, reporting Phase 2 SPMS trial results for furalumab.
- drugFuralumab
Intranasal fully human monoclonal antibody binding CD3, intended to induce Tregs and suppress activated microglia.
- indicationSecondary progressive multiple sclerosis (SPMS)
Patient cohort described as having no specifically approved effective therapy, per the speaker.

